MERCK Kommanditgesellscha... (MKKGY)

PNK: MKKGY · Real-Time Price · USD

27.62

-0.11 (-0.40%)

At close: May 01, 2025, 3:45 PM

-0.40% (1D)

Bid	27.51
Market Cap	60.25B
Revenue (ttm)	21.16B
Net Income (ttm)	2.78B
EPS (ttm)	1.46
PE Ratio (ttm)	18.92
Forward PE	n/a
Analyst	n/a

Ask	27.61
Volume	6,446
Avg. Volume (20D)	125,072
Open	26.79
Previous Close	27.73
Day's Range	27.50 - 27.75
52-Week Range	24.32 - 39.17
Beta	0.70

About MKKGY

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and t...

Sector Healthcare

IPO Date Nov 16, 2007

Employees 59,020

Stock Exchange PNK

Ticker Symbol MKKGY

Website https://www.merckgroup.com

Full Company Profile

News

7 hours ago · zacks.com

MKKGY vs. ZTS: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Merck KGaA (MKKGY) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang fo...

3 days ago · proactiveinvestors.co.uk

Merck KGaA swoops for US group SpringWorks in $3.4bn deal

Germany's Merck KGaA has agreed to acquire US biotech firm SpringWorks Therapeutics for $3.9 billion in cash. The deal, announced on Monday, values SpringWorks at $47 a share and reflects an enterpris...

3 days ago · wsj.com

Germany's Merck Set to Buy SpringWorks in $3.9 Billion Deal

The deal to acquire the U.S. biopharmaceutical company confirms an earlier report in The Wall Street Journal.

3 days ago · reuters.com

Germany's Merck KGaA in $3.9 bln deal to acquire US biotech firm SpringWorks

German healthcare and materials group Merck KGaA said on Monday it struck a deal to acquire U.S. biotech firm SpringWorks Therapeutics for an equity value of $3.9 billion to boost its cancer drug busi...

1 month ago · youtube.com

Resilience is part of our DNA, says Merck KGaA CEO

Belén Garijo, CEO of Merck KGaA, said the German pharmaceutical company has increased its readiness to deal with the ongoing geopolitical uncertainty, and is confident it will continue delivering prof...

1 month ago · seekingalpha.com

Merck KGaA (MKGAF) Q4 2024 Earnings Call Transcript

Merck KGaA (OTCPK:MKGAF) Q4 2024 Results Conference Call March 6, 2025 8:00 AM ET Company Participants Florian Schraeder - Head of Investor Relations Belen Garijo - Group CEO Helene von Roeder - Group...

1 month ago · reuters.com

Merck KGaA sees forex-adjusted earnings growth of up to 8% this year

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor chemicals and for lab equipment in biotech drug production.

2 months ago · reuters.com

Exclusive: Germany's Merck KGaA in talks to buy US cancer biotech firm Springworks, sources say

Merck KGaA , the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics , according to people familiar with the matter...